Patients with subclinical hypothyroidism before 20 weeks of pregnancy have a higher risk of miscarriage: A systematic review and meta-analysis

Yibing Zhang‡, Haoyu Wang‡, Xifeng Pan, Weiping Teng, Zhongyan Shan*

The Endocrine Institute and The Liaoning Provincial Key Laboratory of Endocrine Diseases, Department of Endocrinology and Metabolism, The First Hospital of China Medical University, Shenyang, China

○ These authors contributed equally to this work.
‡ These authors are co-first authors on this work.
* shanzhongyan@medmail.com.cn

Abstract

Objective
To evaluate the relationship between subclinical hypothyroidism (SCH) and the risk of miscarriage before 20 weeks of pregnancy.

Methods
Literature databases were searched, including the PubMed, Web of Science, Embase and Cochrane databases, from January 1, 1980, to December 31, 2015. The following search terms were used: subclinical hypothyroidism, hypothyroidism, thyroid dysfunction, thyroid hypofunction, subclinical thyroid disease, thyroid dysfunction, pregnancy loss, abortion and miscarriage. Studies comparing the prevalence of miscarriage in pregnant women with SCH with those who were euthyroid were selected. From the studies matched, the relative risk (RR) and corresponding 95% confidence interval (95% CI) were calculated to yield outcomes. All the statistical analyses were performed using Review Manager (Revman) Version 5.3 and Stata Version 12.0 software. The publication bias of the studies was assessed by forest plot and Begg’s test, while the stability of the results was evaluated by sensitivity analysis.

Results
Nine articles satisfying the inclusion criteria were analysed. Compared to euthyroid pregnant women, patients with non-treated SCH had a higher prevalence of miscarriage (RR = 1.90, 95% CI 1.59–2.27, P<0.01). Additionally, SCH patients in the international diagnostic criteria group were more likely to suffer miscarriages than those in the ATA diagnostic criteria group (χ² = 11.493, P<0.01). Moreover, there was no difference between patients with treated SCH and euthyroid women (RR = 1.14, 95% CI 0.82–1.58, P = 0.43). Compared to isolated SCH women, the miscarriage risk of SCH patients with thyroid autoimmunity (TAI) was
obviously higher ($RR = 2.47, 95\% CI: 1.77–3.45, P<0.01$), and isolated SCH patients also had a higher prevalence of miscarriages than euthyroid women ($RR = 1.45, 95\% CI: 1.07–1.96, P = 0.02$). A heterogeneity test, forest plot and Begg’s test suggested that there was no significant heterogeneity or publication bias among the included articles, while the result of sensitivity analysis showed that our study exhibited high stability.

**Conclusion**

SCH is a risk factor for miscarriage in women before 20 weeks of pregnancy, and early treatments can reduce the miscarriage rate. Regardless of the diagnostic criteria used, the miscarriage rate increased as long as a pregnant woman was confirmed to have SCH. The results show that the omission diagnostic rate may increase when the ATA diagnostic criteria are used. In addition, SCH patients with TAI have a higher prevalence of miscarriage, while isolated SCH patients also have a higher miscarriage rate than euthyroid women. Thus, we recommend early treatments to avoid adverse pregnancy outcomes and complications.

**Introduction**

Thyroid dysfunction is prevalent in pregnant women, with a morbidity of 2–3%; it is always caused by chronic autoimmune thyroiditis. Moreover, 5–15% women of reproductive age are diagnosed with thyroid autoimmunity, leading to high risk of adverse pregnancy outcomes[1]. Hypothyroidism is the most common type of thyroid dysfunction, and subclinical hypothyroidism (SCH) has a higher prevalence than overt clinical hypothyroidism (OH). The diagnosis of SCH usually relies on laboratory tests due to the lack of significant clinical features of subclinical diseases, and the non-specific performance in pregnancy patients may be associated with lifestyle changes or manifestations brought out by pregnancy itself[2]. Compared to OH, the incidence of complications related to SCH is lower. However, the prevalence of adverse outcomes, including spontaneous miscarriage, placental abruption, preterm birth, foetal distress and preeclampsia, has increased in recent studies[3]. Whether the miscarriage rate in pregnant women with SCH will increase is still controversial. A large-scale cohort study including 10990 pregnant women found that there was no correlation between SCH and miscarriage or other adverse outcomes[4]. Su et al. conducted a follow-up study among 1017 Chinese pregnant women and came to a similar conclusion[5]. However, several large-scale studies carried out by Liu et al.[6] and Negro et al.[7] revealed that SCH significantly increased the risk of miscarriage in pregnant women. Additionally, the risk of miscarriage increased with the elevation of the serum TSH level, which is consistent with Benhadi et al[8]. Therefore, it is necessary to perform a meta-analysis to evaluate the relationship between SCH and the miscarriage rate in women before 20 weeks of pregnancy by combining the data of all relevant studies.

**Materials and methods**

1. Literature search strategy

Literature databases, including the PubMed, Web of Science, Embase and Cochrane databases, were searched for relevant studies published from January 1, 1980, to December 31, 2015. The
search strategy we used in this study is '(subclinical hypothyroidism OR hypothyroidism
OR thyroid dysfunction OR thyroid hypofunction OR subclinical thyroid disease OR thy-
roid disfunction) AND (pregnancy loss OR abortion OR miscarriage)'. Additionally, the
retrospective method was used to find other eligible studies.

2. Inclusion criteria
Cohort studies conducted among women with SCH or normal thyroid function before 20
weeks of pregnancy were included. 'Abortion' or 'miscarriage' was clearly defined as the event
outcome and the primary data from cases and controls could be extracted to calculate the rela-
tive risk (RR), 95% confidence intervals (95% CI) and P values.

3. Data extraction
The following information was carefully extracted from each study independently by two
authors: name of first author, publication year, country of population, diagnostic criteria of
SCH, pregnancy phase and numbers of SCH cases and normal controls. Disagreements
between two authors were resolved by discussion among the research team.

4. Quality assessment of the included studies
The Newcastle-Ottawa Scale (NOS) scoring system was used by two authors to assess the qual-
ity of the included literature. The scoring system is a type of bias risk assessment tool recom-
manded by the Cochrane Collaboration and applied in the evaluation of case-control and
cohort studies. Three major scoring items, including selectivity, comparability and outcomes,
were assessed. As this meta-analysis focused on the relationship between SCH and miscarriage,
we defined 'no history of disease' as 'no history of miscarriages or abortions'. The NOS scores
ranged from zero to nine stars. All the included studies were assessed by two authors, and dis-
agreements were resolved by discussion with the research team. Additionally, a funnel plot
was created to assess the potential publication bias.

5. Statistical analysis
Review manager 5.3 software was used for meta-analysis, and the association of SCH in preg-
nancy and miscarriage was evaluated by odds ratio (OR) and 95% confidence interval (CI).
Heterogeneity between studies was analysed by the Cochrane Q test, and P<0.1 suggested sta-
tistical significance. At the same time, quantitative analysis of heterogeneity was performed by
calculating $I^2$. $I^2$ values exceeding 25%, 50% and 75% were defined as low, moderate and high
heterogeneity, respectively. The random effects model was used when $I^2>50\%$ and the fixed
effects model was used when $I^2<50\%$. Stata 12.0 software was used to conduct Begg’s test and
sensitivity analysis in order to evaluate the publication bias in the included studies. This meta-
analysis follows the PRISMA 2009 (S1 File).

Results
1. Characteristics of included studies
A total of 2018 articles were retrieved from the PubMed, Web of Science, Embase and
Cochrane databases by keyword search A total of 1769 unrelated articles were excluded after
reading the titles and abstracts. After full-text review of 249 articles and the removal of 24
duplicate documents, eventually 9 cohort studies met the inclusion criteria and were included
in this systematic review. The detailed selection procedures are shown in Fig 1. The eligible
studies were published between 2008 and 2015 and proved to be high quality according to the NOS scoring system. The characteristics of each study are shown in Table 1.

2. Meta-analysis results

(1) SCH without interventions and miscarriage. Seven studies reported relevant data on the association between miscarriage and SCH without intervention. Of 3137 SCH patients, 206 women suffered miscarriage, and of 17528 euthyroid women, 399 women suffered miscarriage. The results of the meta-analysis showed that the prevalence of miscarriage in SCH patients was significantly higher (RR = 1.90, 95% CI 1.59–2.27, \( P < 0.01 \)). The result of heterogeneity tests were \( \chi^2 = 5.94, P = 0.43, I^2 = 0\% \), indicating that there was no obvious heterogeneity among the included studies.

Due to the difference in the TSH level used to define SCH, we classified these 7 studies into two subgroups according to the diagnostic criteria. Studies using the American Thyroid Association (ATA) recommended criteria as TSH > 2.5 mIU/L in early pregnancy were considered...
as the ATA diagnosis group and those using TSH greater than the 95th percentile or 97.5th range in healthy women to define SCH were the specific diagnosis group. The association of SCH and miscarriage was analysed in each group, and the prevalence of miscarriage in patients from both groups was clearly higher than euthyroid women (RR = 2.04, 95% CI 1.66–2.51, P < 0.01 vs. RR = 1.58, 95% CI 1.12–2.32, P < 0.01). Additionally, there was no heterogeneity observed between subgroups (Fig 2). To further assess the different risks of miscarriage induced by two diagnostic criteria, SPSS 22.0 software was used to evaluate the association of miscarriage rates in two groups by the Chi-square test. The incidence of miscarriage in the ATA diagnosis group (7.6%) was significantly higher than that in the specific diagnosis group (4.5%) (χ² = 11.493, P < 0.01).

Because the included studies were geographically diverse, another subgroup analysis was performed based on the different countries. The subjects in 7 studies were divided into domestic and overseas groups. Subgroup meta-analysis showed that in both the domestic or overseas populations, pregnant women with SCH have higher miscarriage risks (RR = 2.00, 95% CI 1.61–2.48 vs. RR = 1.69, 95% CI 1.25–2.29). No heterogeneity was observed in each subgroup (Table 2).

(2) Isolated SCH and miscarriage. Meta-analysis of the 3 studies that reported relevant data on the association between miscarriage and isolated SCH obtained a pooled RR of 1.45 (95% CI 1.07–1.96, P = 0.02), indicating that the prevalence of miscarriage in isolated SCH patients was significantly higher than that in women with normal thyroid function (Fig 3).

(3) SCH with treatments and miscarriage. Meta-analysis of 4 studies reported the relevant data on the association between miscarriage and isolated SCH obtained a pooled RR of

| Authors | Year | Country | Diagnostic criteria for SCH | Pregnancy Phase | SCH without intervention(n/N)a | SCH with treatments(n/N)a | SCH + TAI (n/N)a | Isolated SCH (n/N)a | Euthyroid (n/N)a |
|---------|------|---------|-----------------------------|-----------------|-------------------------------|--------------------------|-----------------|-------------------|-----------------|
| Cleary-Goldman et al.[4] | 2008 | U.S. | TSH>97.5th percentile (>4.29 mIU/L), FT4 2.5–97.5th percentile | 10–13 | 1/240 | - | - | - | 60/10021 |
| Su et al.[5] | 2011 | China | TSH>95th percentile (TSH>3.6 mIU/L), FT4 5–95th percentile | <20 | 2/41 | - | - | - | 11/845 |
| Wang et al. [9] | 2012 | China | TSH>2.5 mIU/L, FT4 within the normal range | <12 | 26/168 | 2/28 | - | - | 48/542 |
| Aguayo et al. [10] | 2013 | Spain | 2.5 mIU/L<TSH<10.0 mIU/L, FT4 within the normal range | Early pregnancy | 45/288 | - | - | - | 157/1761 |
| Ajmani et al. [11] | 2013 | India | TSH>3.0 mIU/L, FT4 within the normal range | 13–26 | - | 2/36 | - | - | 8/347 |
| He et al.[12] | 2014 | China | TSH>2.5 mIU/L, FT4 within the normal range | <12 | 32/635 | - | 30/318 | 12/317 | 8/398 |
| Liu et al.[6] | 2014 | China | 2.5 mIU/L<TSH<10.0 mIU/L, FT4 within the normal range | 4–8 | 54/959 | - | 23/204 | 31/755 | 43/1961 |
| Oztas et al. [13] | 2015 | Turkey | TSH>2.5 mIU/L, FT4 within the normal range | Early pregnancy | - | 3/27 | - | - | 3/56 |
| Yang et al. [14] | 2015 | China | TSH>97.5th percentile (5.22–10 mIU/L), FT4 2.5–97.5th percentile | <12 | 46/806 | 49/1236 | 23/201 | 23/605 | 72/2000 |

*a, the number of patients with SCH in each group; N, the total number of subjects in each group.

https://doi.org/10.1371/journal.pone.0175708.t001
1.14 (95%CI 0.82–1.58, P = 0.43), which indicated that there was no statistically significant difference in miscarriage risk of SCH patients accepting effective treatments and pregnant women with euthyroid. Subgroup meta-analysis showed that in both the domestic or overseas populations, SCH with treatments was not associated with miscarriage (RR = 1.08, 95% CI 0.76–1.52, P > 0.05 vs. RR = 2.22, 95% CI 0.75–6.55, P > 0.05). No heterogeneity was observed in each subgroup with $I^2 = 0\%$ (Table 2).

(4) SCH with or without intervention and miscarriage. Two studies compared the influence of SCH with treatments and without intervention on the risk of miscarriage. The results of the meta-analysis indicated that compared with patients that underwent effective drug treatments, the prevalence of miscarriage risk in patients without intervention significantly increased with a combined RR = 1.50 (95% CI 1.03–2.19, P = 0.04) (Fig 4).

(5) SCH with or without thyroid autoimmunity (TAI) and miscarriage. Three eligible studies compared the influence of SCH with TAI and isolated SCH on the risk of miscarriage.

**Table 2.** Subgroup analysis: The prevalence of miscarriage risk in SCH patients without intervention and SCH patients with treatments compared to controls.

| Study or Subgroup | Experimental Events | Total Events | Total Weight | Risk Ratio (95% CI) | P | Heterogeneity test |
|-------------------|---------------------|--------------|--------------|---------------------|---|-------------------|
| **1.1 ATA diagnosis group** | | | | | | |
| casey 2007 | 6 | 598 | 79 | 16011 | 4.6\% | 2.03 [0.89, 4.64] | | |
| jacob 2012 | 33 | 253 | 25 | 533 | 13.5\% | 2.68 [1.63, 4.40] | | |
| liu 2014 | 54 | 959 | 43 | 1961 | 23.1\% | 2.57 [1.73, 3.80] | | |
| negro 2010 | 39 | 642 | 127 | 3481 | 32.3\% | 1.67 [1.17, 2.36] | | |
| wang 2012 | 26 | 169 | 46 | 542 | 18.6\% | 1.75 [1.12, 2.73] | | |
| **Subtotal (95% CI)** | | | | | | |
| Total events | 158 | 322 | 92.1\% | 2.07 [1.70, 2.53] | | |
| Heterogeneity: Chi$^2$ = 4.23, df = 4 (P = 0.38); $I^2$ = 5\% | | | | | |
| Test for overall effect: Z = 7.21 (P < 0.00001) | | | | | |

| **1.1.2 Specific diagnosis group** | | | | | | |
| chen 2014 | 2 | 371 | 21 | 7641 | 1.6\% | 1.96 [0.46, 8.33] | | |
| cleary-goldman 2008 | 1 | 240 | 60 | 10021 | 2.3\% | 0.70 [0.10, 5.00] | | |
| mannisto 2009 | 1 | 224 | 24 | 4719 | 1.8\% | 0.89 [0.12, 6.48] | | |
| sahu 2010 | 1 | 41 | 7 | 552 | 0.8\% | 1.92 [0.24, 15.28] | | |
| su 2011 | 2 | 41 | 19 | 845 | 1.4\% | 2.17 [0.52, 9.00] | | |
| **Subtotal (95% CI)** | | | | | | |
| Total events | 7 | 131 | | | | |
| Heterogeneity: Chi$^2$ = 1.37, df = 4 (P = 0.85); $I^2$ = 0\% | | | | | |
| Test for overall effect: Z = 0.84 (P = 0.40) | | | | | |

| **Total (95% CI)** | | | | | | |
| Total events | 165 | 453 | 100.0\% | 2.02 [1.67, 2.45] | | |
| Heterogeneity: Chi$^2$ = 6.05, df = 9 (P = 0.74); $I^2$ = 0\% | | | | | |
| Test for overall effect: Z = 7.19 (P < 0.00001) | | | | | |
| Test for subgroup differences: Chi$^2$ = 1.02, df = 1 (P = 0.31), $I^2$ = 1.9\% | | | | | |

Fig 2. Forest plots for the prevalence of miscarriage risk in untreated SCH patients diagnosed by ATA criteria and specific criteria compared with controls.

https://doi.org/10.1371/journal.pone.0175708.g002
The result of the meta-analysis indicated that compared with isolated SCH, the prevalence of miscarriage risk in patients with TAI significantly increased with a combined RR = 2.47 (95% CI 1.77–3.45, P < 0.01) (Fig 5).

### 3. Sensitivity analysis

To assess the effects of each individual research and to verify the stability of the results of the meta-analysis, sensitivity analysis was conducted by removing each study in turn and estimating the overall effect of the remaining studies sequentially. In this meta-analysis, only 7 studies reporting relevant data on the association of SCH without intervention and miscarriage were analysed because the number of studies in the other 4 groups was too few to perform a meaningful sensitivity analysis. After removing each individual study, the pooled RR of the remaining 6 studies were all located in the range of the overall effect, indicating that the results of the meta-analysis showed low sensitivity and high stability (Fig 6).

### Table 1: Forest plots for the prevalence of miscarriage risk in SCH with TAI compared to isolated SCH.

| Study or Subgroup | SCH+TAI | Isolated SCH | Risk Ratio | Risk Ratio |
|-------------------|---------|--------------|------------|------------|
|                   | Events  | Total        | Events     | Total      | M-H, Fixed, 95% CI | Year | M-H, Fixed, 95% CI | Year |
| He 2014           | 20      | 318          | 12         | 317        | 32.8%            | 2.66 [0.83, 3.34] | 2014 |
| Liu 2014          | 23      | 204          | 31         | 755        | 36.0%            | 2.75 [1.64, 4.60] | 2014 |
| Yang 2015         | 23      | 201          | 23         | 605        | 31.3%            | 3.01 [1.73, 5.25] | 2015 |
| Total (95% CI)    | 723     | 1677         | 100.0%     | 2.47 [1.77, 3.45] | |
| Total events      | 66      | 66           |            |            | |
| Heterogeneity: Chi² = 1.88, df = 2 (P = 0.39); I² = 0% |
| Test for overall effect: Z = 5.34 (P < 0.00001) |

### Fig 5. Forest plots for the prevalence of miscarriage risk in SCH with TAI compared to isolated SCH.

https://doi.org/10.1371/journal.pone.0175708.g005
4. Publication bias

A funnel plot and Begg’s test were performed to assess whether there was a potential publication bias in the included literature. The general symmetry of the funnel plot indicated that there was no obvious publication bias (Fig 7). As the funnel plot is a subjective and straightforward method, we eventually utilized Begg’s test to obtain statistical evidence to verify the absence of publication bias (P = 0.764).

Discussion

Alterations in the endocrine and metabolic status during pregnancy might contribute to changing levels of thyroid hormones. Several reasons may account for the changes of thyroid function in pregnant women: (1) relative iodine deficiency during pregnancy; (2) the effects of human chorionic gonadotropin (hCG) on the activation of thyroid function stimulates the secretion of thyroid hormones, which could inhibit adenohypophysis function and suppress the levels of thyrotropin; (3) elevated levels of oestrogen during pregnancy, increasing serum thyroid binding globulin (TBG) and raising the concentrations of serum total thyroxine; and (4) the effect of the placenta on thyroxine deiodination[15]. Therefore, the normal reference ranges of TSH for pregnant women differ from those of non-pregnant women. To avoid confusion with euthyroid function or thyroid abnormalities, it is necessary to use specific reference ranges of TSH and thyroid hormones during pregnancy.

Recently, several studies have shown a correlation between SCH in gestation and adverse pregnancy outcomes, including preterm, placental abruption, and gestational diabetes mellitus.
However, the effect of SCH on the risk of miscarriage remains unclear. In our study, we have systemically reviewed the literature published from 2008–2015, providing a basis for understanding the relationship of gestational SCH with miscarriage risk. We report that compared with euthyroid subjects, women with untreated SCH in early pregnancy show a 1.9-fold risk of miscarriage, suggesting that SCH is useful in predicting miscarriage. However, further studies on this matter may be needed to reveal the mechanisms.

The 2011 Guidelines of the ATA and the 2012 Guidelines of TES recommended that the specific reference ranges for TSH in the early, middle and late stages of pregnancy are 0–2.5 mIU/L, 0.2–3.0 mIU/L, and 0.3–3.0 mIU/L, respectively [14, 19], which has been widely adopted by the international community. However, several recent studies have suggested that it is more reasonable to establish pregnancy-specific diagnostic criteria based on the local TSH levels because the assessment of thyroid function varies widely with region and race [20, 21]. The present analysis included studies using different diagnostic criteria, and compared the results of the ATA standard and specific standard. It has been suggested that with either criteria, once SCH is diagnosed, the risk of miscarriage will increase (OR = 2.04, ATA; 1.58, specific standard). Furthermore, the miscarriage rate based on the ATA standard is higher than that based on the specific standard.
Recently, Maraka, et al. [22] reported that pregnancy with SCH is closely associated with a higher foetal mortality (miscarriage rate and stillbirth rate) in a systematic analysis. Data obtained from 3 individual studies based on specific TSH ranges, which included 7 miscarriage cases in 917 SCH patients and 131 cases in 23,778 healthy subjects, showed no significant difference between SCH subjects and healthy controls (RR = 1.38, 95% CI = 0.65–2.96, \( P = 0.40 \)).

Each of these studies indicated no significant differences in miscarriage risk between SCH and healthy subjects. In addition, according to the ATA criteria, we conducted a meta-analysis involving 158 cases of miscarriage in 2,630 individuals with SCH and 322 cases in 22,528 healthy individuals. This suggested an elevated risk of miscarriage for SCH pregnant women compared with healthy controls (RR = 2.07, 95% CI 1.70–2.53, \( P < 0.01 \)) (Fig 8). These results suggested that miscarriage might be undetected due to the use of specific SCH criteria. Therefore, it is more beneficial to pregnancy if the levels of TSH are controlled to under 2.5 mIU/L in early pregnancy.

Currently, it is controversial whether pregnancy with SCH should be treated. ATA Guidelines recommended that TPOAb-positive subjects with TSH > 2.5 mIU/L and normal FT4 or subjects with TSH > 10.0 mIU/L should be treated with L-thyroxine (L-T4) [14]. For TPOAb-negative subjects with TSH > 2.5 mIU/L, there is not enough evidence to support the treatment of L-T4. The TES guidelines recommended that subjects with TSH > 2.5 mIU/L and normal FT4, regardless of TPOAb positivity, should accept L-T4 treatment [1]. The present study suggested that pregnant women with SCH who underwent L-T4 treatment had a significantly lower miscarriage rate than SCH subjects without treatment, whereas no significant difference
was observed between patients with treatment and healthy individuals. This indicates that the treatment rate of SCH during pregnancy should be improved, as it helps to avoid miscarriage. Meanwhile, the miscarriage risk is significantly higher in pregnant women with SCH but who are not TPOAb-positive, which suggests that we also cannot ignore the management of isolated SCH patients.

Thyroid autoantibodies are important indexes to evaluate the status of thyroid autoimmunity. TPOAb plays a role in thyroid damage by activating complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and the killing effect of T-cells. Autoimmune thyroiditis is considered the major cause of SCH. Glinoer et al. [23] showed that thyroid autoantibodies indicate the abnormality of immune function, which induces miscarriage by unstable placenta implantation. Negro et al. [24] suggested that thyroid autoantibodies imply poor thyroid function during pregnancy, which might result in clinical and subclinical hypothyroidism, increasing the risk of miscarriage. Specifically, SCH subjects with TPOAb positivity had a significantly higher miscarriage risk than isolated SCH subjects. Therefore, more attention is required in these populations, and the L-T4 should be considered early to prevent poor pregnancy outcomes.

Our study has several limitations. Firstly, given language limitations, more Chinese studies were included, leading to a certain selection bias. Secondly, several studies used the fetal loss rather than miscarriage as a pregnancy outcome, which were excluded as a result of failure to extract data. Additionally, the SCH diagnostic criteria of the included studies varied with periods and regions. Although we performed subgroup analyses based on the different criteria, the effects cannot be eliminated completely. What is more, among 4 studies concerned about the treatments, 3 of them set up the targets according to ATA recommended criteria (TSH < 2.5 mIU/L at the first trimester and TSH < 3.0 mIU/L at the second and third trimesters), while one research set up the target according to the pregnancy-specific criteria based on the local TSH levels. Given the limitations above, more large-scale prospective surveys are needed.

Conclusion

SCH is a risk factor for miscarriage in women before 20 weeks of pregnancy, and early treatments can reduce the miscarriage rate. With either diagnostic criterion, the risk of miscarriage will increase once SCH is diagnosed. However, specific diagnostic criteria might result in increased diagnosis of miscarriage that would have been missed otherwise. The miscarriage rate is higher in isolated SCH subjects and increases further in SCH pregnant women with positive thyroid autoantibodies.

Supporting information

S1 File. PRISMA 2009 checklist.
(DOC)

Author Contributions

Conceptualization: ZYS WPT.
Data curation: YBZ HYW XFP.
Formal analysis: YBZ HYW.
Funding acquisition: ZYS.
Investigation: YBZ.
Methodology: YBZ HYW ZYS.

Project administration: YBZ.

Resources: YBZ WPT ZYS.

Software: YBZ XFP.

Supervision: YBZ WPT ZYS.

Validation: YBZ ZYS.

Visualization: YBZ HYW.

Writing – original draft: YBZ HYW.

Writing – review & editing: YBZ HYW ZYS.

References

1. van den Boogaard E, Vissenberg R, Land JA, van Wely M, Ven der Post JA, Goddijn M, et al. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. Hum Reprod Update. 2011; 17:605–619. https://doi.org/10.1093/humupd/dmr024 PMID: 21622978

2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160:526–534. PMID: 10695693

3. Teng W, Shan Z, Patil-Sisodia K, Cooper DS. Hypothyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013; 1:228–237. https://doi.org/10.1016/S2213-8587(13)70109-8 PMID: 24622371

4. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF, et al. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol. 2008; 112:85–92. https://doi.org/10.1097/AOG.0b013e3181788dd7 PMID: 18591312

5. Su PY, Huang K, Hao JH, Xu YQ, Yan SQ, Li T, et al. Maternal Thyroid Function in the First Twenty Weeks of Pregnancy and Subsequent Fetal and Infant Development: A Prospective Population-Based Cohort Study in China. J Clin Endocrinol Metab. 2011; 96:3234–3241. https://doi.org/10.1210/jc.2011-0274 PMID: 21832110

6. Liu H, Shan Z, Li C, Mao J, Xie X, Wang W, et al. Maternal Subclinical Hypothyroidism, Thyroid Autoimmunity and the Risk of Miscarriage: A Prospective Cohort Study. Thyroid. 2014; 24:1642–1649. https://doi.org/10.1089/thy.2014.0029 PMID: 25087688

7. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab. 2010; 95:E44–48. https://doi.org/10.1210/jc.2010-0340 PMID: 20534758

8. Benthadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol. 2009; 160:985–991. https://doi.org/10.1530/EJE-08-0953 PMID: 19273570

9. Wang S, Teng WP, Li JX, Wang WW, Shan ZY. Effects of maternal subclinical hypothyroidism on obstetrical outcomes during early pregnancy. J EndocrinolInvest. 2012; 35:322–325.

10. Aguayo A, Grau G, Vela A, Aniel-Quiroga A, Espada M, Martul P, et al. Urinary iodine and thyroid function in a population of healthy pregnant women in the north of Spain. J Trace Elem Med Biol. 2013; 27:302–306. https://doi.org/10.1016/j.jtemb.2013.07.002 PMID: 23992867

11. Ajmani SN, Aggarwal D, Bhatia P, Sharma M, Sarabhai V, Paul M. Prevalence of overt and subclinical thyroid dysfunction among pregnant women and its effect on maternal and fetal outcome. J Obstet Gynaecol India. 2014; 64:105–110.

12. He Y, He T, Wang Y, Xu Z, Xu Y, Wu Y, et al. Comparison of the effect of different diagnostic criteria of subclinical hypothyroidism and positive TPO-Ab on pregnancy outcomes. Zhonghua Fu Chan Ke Za Zhi. 2014; 49:824–828. PMID: 25603906

13. Oztas E, Erkenekli K, Ozler S, Aktas A, Buyukkagnici U, Uygur D, et al. First trimester interleukin-6 levels help to predict adverse pregnancy outcomes in both thyroid autoantibody positive and negative patients. J Obstet Gynaecol Res. 2015; 41:1700–1707. https://doi.org/10.1111/jog.12799 PMID: 26311506
14. Yang J, Guo H, Ding S, Tao B, Zhang X. Effect of the treatment acceptance on the perinatal outcomes in women with subclinical hypothyroidism, positive thyroid gland peroxidase antibody in early pregnancy. Zhonghua Fu Chan Ke Za Zhi. 2015; 50:652–657. PMID: 26675390

15. Negro R, Stagnaro-Green A. Diagnosis and management of subclinical hypothyroidism in pregnancy. BMJ. 2014;6; 349:g4929. https://doi.org/10.1136/bmj.g4929 PMID: 25288580

16. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005; 105:239–245. https://doi.org/10.1097/01.AOG.0000152345.99421.22 PMID: 15684146

17. Karakosta P, Alegakis D, Georgiou V, Roumeliotaki T, Fthenou E, Vassilaki M, et al. Thyroid dysfunction and autoantibodies in early pregnancy are associated with increased risk of gestational diabetes and adverse birth outcomes. J Clin Endocrinol Metab. 2012; 97:4464–4472. https://doi.org/10.1210/jc.2012-2540 PMID: 23015651

18. Wang S, Li M, Chu D, Liang L, Zhao X, Zhang J. Clinical or subclinical hypothyroidism and thyroid autoantibody before 20 weeks pregnancy and risk of preterm birth: a systematic review. Zhonghua Fu Chan Ke Za Zhi. 2014; 49:816–822. PMID: 25603905

19. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97:2543–2565. https://doi.org/10.1210/jc.2011-2803 PMID: 22869843

20. Bliddal S, Feldt-Rasmussen U, Boas M, Faber J, Juul A, Larsen T, et al. Gestational-age-specific reference ranges from different laboratories misclassify pregnant women's thyroid status: comparison of two longitudinal prospective cohort studies. Eur J Endocrinol. 2013; 170:329–339. https://doi.org/10.1530/EJE-13-0672 PMID: 24277773

21. Li C, Shan Z, Mao J, Wang W, Xie X, Zhou W, et al. Assessment of thyroid function during first-trimester pregnancy: what is the rational upper limit of serum TSH during the first trimester in Chinese pregnant women? J Clin Endocrinol Metab. 2014; 99:73–79. https://doi.org/10.1210/jc.2013-1674 PMID: 24276458

22. Maraka S, Singh Ospina NM, O’Keefee DT, Espinosa De Ycaza AE, Gionfriddo MR, et al. Subclinical Hypothyroidism in Pregnancy: A Systematic Review and Meta-Analysis. Thyroid. 2016; 26(4):580–590. https://doi.org/10.1089/thy.2015.0418 PMID: 26837268

23. Glinoer D. Miscarriage in women with positive anti-TPO antibodies: is thyroxine the answer? J Clin Endocrinol Metab. 2006; 91:2500–2502. https://doi.org/10.1210/jc.2006-0834 PMID: 16825575

24. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab. 2006; 91:2587–2591. https://doi.org/10.1210/jc.2005-1603 PMID: 16621910